Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, ...

Telitacicept has the first regulatory approval for Sjögren disease (China), while global phase 3 programs aim to support ...

Without a functioning ACIP, Jeffery Goad, PharmD, MPH, explains who now guides COVID-19 vaccine use and how HMOs can stock ...

Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, says Catherine Varney, DO. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

BC, discusses how data builds payer trust, reduces prior authorization, and expands access in community oncology. In one of its most recent pilots, AON partnered with Evolent Health and a specific ...

CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

CMS is accelerating downside risk in value-based care (VBC), even though many clinicians, practices, and health systems lack the operational and measurement infrastructure needed ...

Rotterdam-based diagnosis (2 of oligo/anovulation, hyperandrogenism, polycystic ovarian morphology) persists, but ...

Both 340B stakeholders endorsed an independent data clearinghouse and statutory patient definition amid program growth ...

Lung cancer screening eligibility increased markedly from 2018–2023 under USPSTF criteria, reflecting aging and substantial ...

Diagnosed atopic dermatitis (AD) affected about 6.9 million insured people in the US in 2023, but roughly half of them filled ...

LIBERTY met all primary/secondary endpoints, with lower 6-day TEAEs/ISRs/hypersensitivity (56.5% vs 91.4%) and systemic AEs ...